Exemestane clinical trials
Also written Aromasin, FCE-24304 and PNU 155971.
ClinicalTrials.gov finds 400 studies for exemestane. How that becomes 117 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives exemestane. Its counts are asked again every night. How drug pages count
- 400Found by its intervention search · See all 400 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 290 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −6
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast CancerNCT01231659 · Earlier treatment; the study gives letrozole with everolimusReport a problem
- Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and ExemestaneNCT01773460 · Earlier treatment; the study continues everolimus with another endocrine drugReport a problem
- Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication UptakeNCT02517593 · Named as a preventive option; not givenReport a problem
- the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile WomenNCT04619914 · Named only in a description of letrozole; not givenReport a problem
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerNCT05607004 · Not among the study's treatments; named in keywords and exclusionsReport a problem
- Skipping Hormone Therapy in Low-Risk Early Breast CancerNCT07661927 · Not given; the study omits endocrine therapyReport a problem
- 394Give exemestane to participants
- −43Observe patients on it, or give it outside a trial
- −41Compare another treatment with it
- −193Give it beside what is tested
- 117Test it: the count on this site
Get an email when these change. Save the exemestane studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Oct 1999 · AROMASIN · NDA 020753 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
115 studies that test it; most in 2001 (9)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1998 | 2 |
| 1999 | 1 |
| 2000 | 2 |
| 2001 | 9 |
| 2002 | 5 |
| 2003 | 6 |
| 2004 | 5 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 8 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 102
Pfizer (9) · Fudan University (6) · ETOP IBCSG Partners Foundation (5) · National Cancer Institute (NCI) (4) · Spanish Breast Cancer Research Group (3) · NCIC Clinical Trials Group (3) · Memorial Sloan Kettering Cancer Center (3) · Roxane Laboratories (3)
Often tested with
Tested in the same studies.
Anastrozole (39) · Tamoxifen (21) · Letrozole (14) · Palbociclib (7) · Trastuzumab (6) · Capecitabine (5) · Hormone Therapy (5) · Goserelin (4)
Related medicines
As reviewed, each with the page that says it.
- One of Aromatase inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 15 phase 3 studies under way
Exemestane is the comparator. A study of two new drugs counts under both.
- 2Elacestrant · Stemline Therapeutics, Inc., European Organisation for Research and Treatment of Cancer - EORTC · next primary completion Aug 2029
- 2Giredestrant · Genentech, Inc., Hoffmann-La Roche
- 2AZD9833 · AstraZeneca · next primary completion Apr 2027
- 2Imlunestrant · Eli Lilly and Company · next primary completion Oct 2027
- 2HRS-8080 · Shandong Suncadia Medicine Co., Ltd. · next primary completion Aug 2027
- 1Letrozole · Stemline Therapeutics, Inc. · next primary completion Aug 2029
- 1Tamoxifen · Stemline Therapeutics, Inc. · next primary completion Aug 2029
- 1Palazestrant · Olema Pharmaceuticals, Inc.
New treatments tested with it · 8 most studied
New when their studies opened, with exemestane beside them; studies of each.
Reaching primary completion within a year · 4
Studies that test exemestane.
- Jan 2027Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScorePhase 2 · Washington University School of Medicine
- Jan 2027Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.Phase 2 · Andrea DeCensi
- Aug 2027Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerPhase 2 · Dana-Farber Cancer Institute
- Nov 2027An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerPhase 2 · Anhui Provincial Cancer Hospital
Studies
Open first, then newest update. How each study uses exemestane has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 117
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerRecruitingPhase 2Medical College of WisconsinNCT06361940One endocrine option for weeks before surgery; resistance pathways studiedReport a problem
- A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before SurgeryRecruitingNot applicableMemorial Sloan Kettering Cancer CenterNCT06127979One endocrine option for two weeks before surgeryReport a problem
- E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen StudyRecruitingPhase 1University of North Carolina, Chapel HillNCT07706374Two doses and two durations to induce ovulation in PCOSWritten as Exemestane 25 MGReport a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older womenReport a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786One endocrine option alone, before or instead of surgery in older womenWritten as ExemestaneReport a problem
- Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskRecruitingPhase 2UNICANCERNCT05297617One aromatase inhibitor for two years instead of fiveReport a problem
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerRecruitingPhase 2Peking University People's HospitalNCT06970912One aromatase inhibitor with dalpiciclib before surgery, against chemotherapyReport a problem
- Pre-Operative Window of ET to Inform RT Decisions (POWER II)RecruitingPhase 3University of VirginiaNCT06507618One endocrine option for 90 days before surgery, against surgery firstReport a problem
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07483307One endocrine option before surgery in lobular breast cancerReport a problem
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingPhase 2European Institute of OncologyNCT07395336With elacestrant in FES-avid metastatic breast cancerWritten as elacestrant and exemestaneReport a problem
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07499999Low dose, against low-dose tamoxifen, in women at high riskWritten as ExemestaneReport a problem
- Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)RecruitingPhase 2Centre Leon BerardNCT03624244One aromatase inhibitor, continued or interrupted, in endometrial stromal sarcomaReport a problem
- Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT07071038One aromatase inhibitor switched to for side effects, against supportive careReport a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07299890With palbociclib, trastuzumab and pertuzumab before surgeryWritten as Trastuzumab and Pertuzumab Combination with Palbociclib and ExemestaneReport a problem
- Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingPhase 2Andrea DeCensiNCT06364267Low dose, against low-dose tamoxifen, in women at high riskWritten as Exemestane 25 MGReport a problem
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialNot yet recruitingPhase 3Fudan UniversityNCT07153757One endocrine option for two to three years instead of fiveReport a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 3Fudan UniversityNCT07005557One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older patientsReport a problem
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingPhase 3Region Örebro CountyNCT06223698One aromatase inhibitor in extended adjuvant therapy, against tamoxifen or shorter useWritten as ExemestaneReport a problem
- Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06656624One aromatase inhibitor with ribociclib, against chemotherapy firstReport a problem
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)RecruitingPhase 3Peking Union Medical College HospitalNCT05861830One endocrine option with dalpiciclib, against chemotherapyReport a problem
See all 117 studies that test exemestane →
Tested on its own · 33 — no other medicine in its arm
- A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before SurgeryRecruitingNot applicableMemorial Sloan Kettering Cancer CenterNCT06127979One endocrine option for two weeks before surgeryReport a problem
- E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen StudyRecruitingPhase 1University of North Carolina, Chapel HillNCT07706374Two doses and two durations to induce ovulation in PCOSWritten as Exemestane 25 MGReport a problem
- Exemestane in Treating Postmenopausal Women With Stage IV Breast CancerCompletedPhase 2City of Hope Medical CenterNCT00810797Given two weeks out of three in metastatic breast cancerWritten as exemestaneReport a problem
- Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial CancerCompletedPhase 2National Cancer Institute (NCI)NCT03300557Before surgery in endometrial hyperplasia or low-grade cancerWritten as ExemestaneReport a problem
- Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02CompletedNot applicableETOP IBCSG Partners FoundationNCT00963417With triptorelin, against tamoxifen; bone density measuredReport a problem
- Exemestane in Hormone Receptor Positive High Grade Ovarian CancerTerminatedPhase 3Ente Ospedaliero Ospedali GallieraNCT04460807Added to first-line chemotherapy in ovarian cancer, against placeboWritten as ExemestaneReport a problem
- Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast CancerCompletedPhase 3NCIC Clinical Trials GroupNCT00083174To prevent breast cancer in women at high riskWritten as exemestaneReport a problem
- Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerCompletedPhase 3NCIC Clinical Trials GroupNCT00066573Against anastrozole after surgeryWritten as exemestaneReport a problem
- Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT02598557Daily, three times weekly or weekly before surgeryWritten as ExemestaneReport a problem
- Exemestane in Post-Menopausal Women With NSCLCCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT02666105Added in lung cancer progressing on checkpoint inhibitorsWritten as ExemestaneReport a problem
- Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer PatientsCompletedPhase 2Spanish Breast Cancer Research GroupNCT00128843Against anastrozole, first line in metastatic breast cancerWritten as ExemestaneReport a problem
- Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCompletedPhase 4PfizerNCT01176916After tamoxifen in Chinese patientsWritten as Aromasin (exemestane)Report a problem
- Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02CompletedNot applicableETOP IBCSG Partners FoundationNCT00975676With triptorelin; estrogen suppression measuredReport a problem
- Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast CancerCompletedNot applicableNCIC Clinical Trials GroupNCT00066586Against placebo to reduce breast densityWritten as exemestaneReport a problem
- A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP)Status unknownPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT03137368With ovarian suppression, against tamoxifen in CYP2D6*10 carriersWritten as Exemestane TabletsReport a problem
- Bioequivalency Study of Exemestane 25 mg Tablet Under Fed ConditionsCompletedNot applicableRoxane LaboratoriesNCT01331434Bioequivalence of a generic tablet, fedWritten as exemestaneReport a problem
- Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCompletedNot applicableRoxane LaboratoriesNCT01331421Bioequivalence of a generic tablet, fastedWritten as exemestaneReport a problem
- Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCompletedNot applicableRoxane LaboratoriesNCT01331447A pilot bioequivalence study, fastedWritten as exemestaneReport a problem
- Exemestane or Docetaxel-Cytoxan in Low Recurrence Score CancersCompletedPhase 2Emory UniversityNCT00941330Before surgery, against docetaxel and cyclophosphamideWritten as ExemestaneReport a problem
- Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast CancerCompletedPhase 3PfizerNCT00038467Switched to after tamoxifen, against continuing tamoxifenWritten as ExemestaneReport a problem
Showing 20 of 33. See all 33 →
Tested with established drugs · 7 — they are given beside it
- Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingPhase 2Guangdong Provincial People's HospitalNCT04858516With palbociclib, trastuzumab and pyrotinib before surgeryWritten as palbociclib and exemestane plus trastuzumab and pyrotinibReport a problem
- Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedPhase 3ETOP IBCSG Partners FoundationNCT00066703With triptorelin, against tamoxifen with triptorelinWritten as exemestaneReport a problem
- Biology Guided Therapy for Breast Cancer for ER PositiveTerminatedPhase 2Inova Health Care ServicesNCT04965688One therapy a biopsy test may chooseReport a problem
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast CancerTerminatedPhase 3ARCAGY/ GINECO GROUPNCT01303679With bevacizumab, against paclitaxel with bevacizumabWritten as ExemestaneReport a problem
- Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerCompletedNot applicableUniversity of ArizonaNCT01385280After estradiol in metastatic breast cancerWritten as exemestaneReport a problem
- Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast CancerCompletedPhase 2Georgetown UniversityNCT00073073To reduce breast density in women at high riskWritten as ExemestaneReport a problem
- Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerStatus unknownPhase 3Fudan UniversityNCT00902954Switched to after anastrozole or letrozole, against continuing themWritten as exemestaneReport a problem
Tested in a combination · 77 — another drug in the study is under test too
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerRecruitingPhase 2Medical College of WisconsinNCT06361940One endocrine option for weeks before surgery; resistance pathways studiedReport a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older womenReport a problem
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786One endocrine option alone, before or instead of surgery in older womenWritten as ExemestaneReport a problem
- Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskRecruitingPhase 2UNICANCERNCT05297617One aromatase inhibitor for two years instead of fiveReport a problem
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerRecruitingPhase 2Peking University People's HospitalNCT06970912One aromatase inhibitor with dalpiciclib before surgery, against chemotherapyReport a problem
- Pre-Operative Window of ET to Inform RT Decisions (POWER II)RecruitingPhase 3University of VirginiaNCT06507618One endocrine option for 90 days before surgery, against surgery firstReport a problem
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07483307One endocrine option before surgery in lobular breast cancerReport a problem
- Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingPhase 2European Institute of OncologyNCT07395336With elacestrant in FES-avid metastatic breast cancerWritten as elacestrant and exemestaneReport a problem
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07499999Low dose, against low-dose tamoxifen, in women at high riskWritten as ExemestaneReport a problem
- Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)RecruitingPhase 2Centre Leon BerardNCT03624244One aromatase inhibitor, continued or interrupted, in endometrial stromal sarcomaReport a problem
- Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT07071038One aromatase inhibitor switched to for side effects, against supportive careReport a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07299890With palbociclib, trastuzumab and pertuzumab before surgeryWritten as Trastuzumab and Pertuzumab Combination with Palbociclib and ExemestaneReport a problem
- Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingPhase 2Andrea DeCensiNCT06364267Low dose, against low-dose tamoxifen, in women at high riskWritten as Exemestane 25 MGReport a problem
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialNot yet recruitingPhase 3Fudan UniversityNCT07153757One endocrine option for two to three years instead of fiveReport a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 3Fudan UniversityNCT07005557One aromatase inhibitor with a CDK4/6 inhibitor, without chemotherapy, in older patientsReport a problem
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingPhase 3Region Örebro CountyNCT06223698One aromatase inhibitor in extended adjuvant therapy, against tamoxifen or shorter useWritten as ExemestaneReport a problem
- Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06656624One aromatase inhibitor with ribociclib, against chemotherapy firstReport a problem
- Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)RecruitingPhase 3Peking Union Medical College HospitalNCT05861830One endocrine option with dalpiciclib, against chemotherapyReport a problem
- Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04023292One endocrine option for two or four weeks before surgeryReport a problem
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsCompletedPhase 2National Cancer Institute (NCI)NCT06169124With darolutamide and leuprolide in recurrent granulosa cell tumoursWritten as ExemestaneReport a problem
Showing 20 of 77. See all 77 →
Beside an established treatment under test · 33 — an approved drug, surgery or radiation is what the study tests
Tested with exemestane: Everolimus 7 · entinostat 4 · xentuzumab 2 · palbociclib 2 · Surgery or a procedure 1 · enzalutamide 1 · radium Ra 223 dichloride 1 · tucidinostat 1
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02115282In every armGiven in both arms; the study adds entinostatWritten as ExemestaneReport a problem
- Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedPhase 2PfizerNCT02007512In every armGiven in both arms; the study adds enzalutamideWritten as exemestaneReport a problem
- BI 836845 in Estrogen Receptor Positive Metastatic Breast CancerCompletedPhase 1Boehringer IngelheimNCT02123823In every armGiven in all arms with everolimus; the study adds xentuzumabWritten as ExemestaneReport a problem
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadCompletedPhase 2Boehringer IngelheimNCT03659136In every armGiven in both arms with everolimus; the study adds xentuzumabWritten as ExemestaneReport a problem
- Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast CancerCompletedPhase 2Queen Mary University of LondonNCT02676986Given in both ER-positive groups; the study adds enzalutamideWritten as ExemestaneReport a problem
- A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorCompletedPhase 2Novartis PharmaceuticalsNCT03312738In every armGiven in both arms; the study adds everolimusWritten as ExemestaneReport a problem
- Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerCompletedPhase 2BayerNCT02258451In every armGiven in both arms with everolimus; the study adds radium-223Written as ExemestaneReport a problem
- Palbociclib With Everolimus + Exemestane In BCCompletedPhase 1/2Dana-Farber Cancer InstituteNCT02871791In every armBackbone with everolimus; palbociclib is addedWritten as ExemestaneReport a problem
- Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerCompletedPhase 2Kyowa Kirin Co., Ltd.NCT03291886In every armGiven in both arms; the study adds entinostatWritten as ExemestaneReport a problem
- Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerCompletedPhase 2Syndax PharmaceuticalsNCT00676663In every armGiven in both arms; the study adds entinostatWritten as exemestaneReport a problem
- Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedPhase 3Chipscreen Biosciences, Ltd.NCT02482753In every armGiven in all arms; the study adds chidamideWritten as exemestaneReport a problem
- PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast CancerStatus unknownPhase 2Hamdy A. AzimNCT02917005In every armGiven in both arms with goserelin; the study adds palbociclibWritten as ExemestaneReport a problem
- Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast CancerStatus unknownPhase 3Taizhou EOC Pharma Co., Ltd.NCT03538171In every armGiven in both arms; the study adds entinostat in Chinese patientsWritten as ExemestaneReport a problem
- Exemestane-RAD001-MetforminTerminatedPhase 2M.D. Anderson Cancer CenterNCT01627067In every armBackbone with everolimus; the study adds metforminWritten as ExemestaneReport a problem
- Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedPhase 3Novartis PharmaceuticalsNCT03176238In every armBackbone of everolimus in a safety studyWritten as exemestaneReport a problem
- An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker AnalysisCompletedPhase 4Novartis PharmaceuticalsNCT01743560In every armBackbone with everolimus; epigenetic markers are studiedWritten as ExemestaneReport a problem
- A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyCompletedPhase 2Janssen Research & Development, LLCNCT01381874The comparator alone, and beside abiraterone in one armWritten as ExemestaneReport a problem
- A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)CompletedPhase 2Merck Sharp & Dohme LLCNCT01605396In every armGiven in both arms with ridaforolimus; the study adds dalotuzumabWritten as ExemestaneReport a problem
- Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerWithdrawnPhase 2GlaxoSmithKlineNCT00615524Alone or with pazopanib after other hormone therapyWritten as exemestane and pazopanibReport a problem
- Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleCompletedPhase 3Novartis PharmaceuticalsNCT00863655In every armGiven in both arms; the study adds everolimusWritten as ExemestaneReport a problem
Showing 20 of 33. See all 33 →
Beside a new treatment under test · 34 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with exemestane: entinostat 3 · Alpelisib 2 · tucidinostat 2 · ribociclib 2 · alobresib 2 · abemaciclib 1 · dalpiciclib 1 · E-7090 1
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Partner of new EP0062 with everolimus in one moduleWritten as ExemestaneReport a problem
- Sapu003 in Advanced mTOR-sensitive Solid TumorsRecruitingPhase 1SAPU NANO (US) LLCNCT07369505Partner of new Sapu003 in breast cancerWritten as Exemestane 25 MGReport a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingPhase 1Hunan Cancer HospitalNCT07163481Partner of sacituzumab govitecan in one moduleWritten as Sacituzumab Govitecan + Anastrozole / ExemestaneReport a problem
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedPhase 1Eisai Co., Ltd.NCT04572295Partner of new E7090 in one partWritten as ExemestaneReport a problem
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingPhase 1Eli Lilly and CompanyNCT02057133Partner of abemaciclib, alone or with everolimusWritten as ExemestaneReport a problem
- BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT01870505Partner of alpelisib in some armsWritten as ExemestaneReport a problem
- Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT01594216In every armPartner of ruxolitinib in breast cancerWritten as ExemestaneReport a problem
- Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBCTerminatedEarly Phase 1UNC Lineberger Comprehensive Cancer CenterNCT03361800Given with or without entinostat before surgery, named in the full titleReport a problem
- Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedPhase 1Tianjin Hemay Pharmaceutical Co., LtdNCT03308201Partner of new Hemay022, dose-findingWritten as Hemay022+exemestaneReport a problem
- Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant TreatmentActive, not recruitingNot applicableShengjing HospitalNCT05132790Partner of new dalpiciclib after radiotherapy, before surgeryReport a problem
- Neoadjuvant Tucidinostat and Exemestane in Early Breast CancerCompletedPhase 2First Affiliated Hospital, Sun Yat-Sen UniversityNCT04465097In every armPartner of new tucidinostat before surgeryWritten as ExemestaneReport a problem
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerCompletedPhase 2Novartis PharmaceuticalsNCT01698918In every armPartner of everolimus in second lineWritten as ExemestaneReport a problem
- Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerTerminatedPhase 1/2National Taiwan University HospitalNCT02990845In every armPartner of pembrolizumab with leuprolide in premenopausal womenWritten as Pembrolizumab/ Exemestane/ LeuprolideReport a problem
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedPhase 2Calithera Biosciences, IncNCT02049957Partner of sapanisertib in some armsWritten as ExemestaneReport a problem
- Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerCompletedPhase 1Kyowa Kirin Co., Ltd.NCT02623751In every armPartner of new KHK2375Written as ExemestaneReport a problem
- Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast CancerStatus unknownPhase 2/3Shengjing HospitalNCT05253066Partner of new chidamide, against chemotherapy before surgeryWritten as Chidamide combined with exemestane (+/- goserelin)Report a problem
- Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerCompletedPhase 1Syndax PharmaceuticalsNCT01594398In every armPartner of entinostat in a food-effect studyWritten as ExemestaneReport a problem
- Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedPhase 1/2Novartis PharmaceuticalsNCT02732119In every armPartner of ribociclib with everolimusWritten as ExemestaneReport a problem
- Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCompletedPhase 1Novartis PharmaceuticalsNCT01857193In every armPartner of ribociclib, with or without everolimusWritten as ExemestaneReport a problem
- A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsStatus unknownPhase 1Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.NCT03125746Partner of new LXI-15029 in one armWritten as LXI-15029+ExemestaneReport a problem
Showing 20 of 34. See all 34 →
Beside supportive care · 14 — a supportive treatment or test is studied
- BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNot yet recruitingPhase 1/2University of Illinois at ChicagoNCT07596212One aromatase inhibitor taken while bupropion is tested for low sexual desireReport a problem
- Tai Chi for Reducing Aromatase Inhibitor-Induced ArthralgiaRecruitingNot applicableThomas Jefferson UniversityNCT07737951One aromatase inhibitor taken while Tai Chi is tested for joint painReport a problem
- Alcohol and Breast Cancer (ABC) TrialCompletedNot applicableBeth Israel Deaconess Medical CenterNCT05423730One aromatase inhibitor taken while light alcohol's effect on hormones is testedReport a problem
- Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenCompletedPhase 2Jules Bordet InstituteNCT02028364In every armWith everolimus while PET imaging is tested as a biomarkerWritten as ExemestaneReport a problem
- Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast CancerCompletedNot applicableUniversity of Maryland, BaltimoreNCT00641303One aromatase inhibitor taken while acupuncture is tested for joint painReport a problem
- Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or LetrozoleCompletedNot applicableOhio State University Comprehensive Cancer CenterNCT01478477One aromatase inhibitor taken while omega-3 is tested for joint symptomsReport a problem
- Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR InhibitorCompletedNot applicableUNICANCERNCT02444390In every armWith everolimus while a biomarker of benefit is testedReport a problem
- Dose EScalation Induction of EvERolimusCompletedPhase 2German Breast GroupNCT02387099In every armWith everolimus while a gradual dose start is testedReport a problem
- Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCTCompletedPhase 3Comprehensive Support Project for Oncology ResearchNCT02376985In every armWith everolimus while dental care is tested against mouth soresReport a problem
- Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneStatus unknownNot applicableAmsterdam UMC, location VUmcNCT02109913In every armStandard treatment with everolimus, during which biomarkers are studiedWritten as Everolimus plus ExemestaneReport a problem
- Breast Cancer Women on Aromatase Inhibitors TreatmentStatus unknownPhase 4Parc de Salut MarNCT03811509One aromatase inhibitor taken while bone treatment is givenReport a problem
- Breast Cancer, Sexuality and Black CohoshStatus unknownPhase 4Irmandade da Santa Casa de Misericordia de Sao PauloNCT02467686In every armOne hormone therapy taken while black cohosh is testedWritten as exemestaneReport a problem
- Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerCompletedPhase 2Novartis PharmaceuticalsNCT02069093In every armWith everolimus while a steroid mouthwash is tested against stomatitisWritten as ExemestaneReport a problem
- Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PDStatus unknownNot applicableNational University Hospital, SingaporeNCT01655004In every armStandard treatment whose benefit a genotype may predictWritten as ExemestaneReport a problem
One option of several · 111 — a test or a strategy chooses among drugs
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingPhase 1/2RayzeBio, Inc.NCT06590857One endocrine partner of new RYZ101Report a problem
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruitingPhase 3National Cancer Institute (NCI)NCT07391774In every armOne endocrine partner of ribociclib in both arms; chemotherapy first is comparedWritten as ExemestaneReport a problem
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingPhase 2Eli Lilly and CompanyNCT07935317In every armOne endocrine choice beside new tersolisibWritten as ExemestaneReport a problem
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239One optional endocrine therapy with HER2 maintenanceReport a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336In every armOne endocrine option in both arms; tersolisib is addedWritten as ExemestaneReport a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751One endocrine option, with a CDK4/6 inhibitor or with saruparibWritten as ExemestaneReport a problem
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationPhase 3Tolmar Inc.NCT05645536In every armOne endocrine partner of new TOL2506, an extensionWritten as Exemestane TabletsReport a problem
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingPhase 1Finn, Olivera, PhDNCT06218303One endocrine option in both arms; a MUC1 vaccine is addedReport a problem
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingPhase 2Puma Biotechnology, Inc.NCT06369285One endocrine partner of alisertibReport a problem
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303In every armOne endocrine partner of abemaciclib while FFNP-PET predicts responseWritten as ExemestaneReport a problem
- Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07796880One aromatase inhibitor in both arms; new culmerciclib is addedReport a problem
- Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast CancerRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07810088One endocrine partner of dalpiciclib and olmesartanReport a problem
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840One aromatase inhibitor in both arms; QL1706 is addedReport a problem
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingPhase 2University of California, San DiegoNCT07729046One endocrine option in both arms; neratinib is addedReport a problem
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingPhase 2Oana DanciuNCT05467891In every armOne endocrine partner of ribociclib after locoregional recurrenceWritten as ExemestaneReport a problem
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT07708194One endocrine partner of entinostat and pyrotinibReport a problem
- Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNot applicableWest China HospitalNCT07687225One standard therapy option; primary tumour surgery is testedReport a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139One endocrine partner of new STX-478Written as ExemestaneReport a problem
- Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07618923One aromatase inhibitor with dalpiciclib before SHR-A1811Report a problem
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07610720One endocrine partner of dalpiciclib with HER2 therapyReport a problem
Showing 20 of 111. See all 111 →
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 41 — what is tested is compared with exemestane
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953One standard chemoprevention option, the comparatorWritten as ExemestaneReport a problem
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingPhase 3PfizerNCT07062965The comparator with everolimus, against prifetrastat with fulvestrantWritten as ExemestaneReport a problem
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951One standard endocrine option, against camizestrantWritten as ExemestaneReport a problem
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364One standard endocrine option, against elacestrantWritten as Exemestane 25 MGReport a problem
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596One physician's choice, against opevesostatWritten as ExemestaneReport a problem
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173One physician's choice, against HRS-8080Written as Exemestane tabletsReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingPhase 2MedSIRNCT06486883One endocrine option with a CDK4/6 inhibitor, against trastuzumab deruxtecanReport a problem
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05472792One endocrine option, the comparator against partial breast radiationWritten as tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifeneReport a problem
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07349069One standard endocrine option, against HRS-8080 after surgeryWritten as Exemestane tabletsReport a problem
- Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerNot yet recruitingPhase 2Yeon Hee ParkNCT06849947One physician's choice, against ribociclib with fulvestrantReport a problem
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingPhase 3Japanese Foundation for Cancer ResearchNCT07190443One endocrine option in both arms; abemaciclib is addedWritten as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenReport a problem
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingPhase 2Yonsei UniversityNCT06837792One endocrine choice, against trastuzumab deruxtecan in HER2-low cancerReport a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT04985266One standard endocrine option, against palbociclib with fulvestrantWritten as ExemestaneReport a problem
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceActive, not recruitingPhase 3Stemline Therapeutics, Inc.NCT06492616One standard endocrine option, against elacestrantWritten as ExemestaneReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340One physician's choice with everolimus, against giredestrantWritten as ExemestaneReport a problem
- ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast CancerActive, not recruitingPhase 3Azienda Ospedaliero-Universitaria CareggiNCT04134598One endocrine option, the comparator against radiotherapy in women over 70Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenReport a problem
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04961996One physician's choice option, against giredestrantReport a problem
- Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialSuspendedPhase 3Alliance for Clinical Trials in OncologyNCT06671912One standard endocrine option, against low-dose tamoxifenWritten as ExemestaneReport a problem
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06428396The comparator with everolimus, against belzutifan with fulvestrantWritten as ExemestaneReport a problem
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingPhase 2PfizerNCT06105632The comparator with everolimus, against atirmociclib with fulvestrantWritten as ExemestaneReport a problem
Showing 20 of 41. See all 41 →
Observed · 43 — patients on it are followed, or it is given outside a trial
- Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine TherapyRecruitingShengjing HospitalNCT04476485One extended endocrine therapy guided by a predictor, observedReport a problem
- First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingPfizerNCT04767594One endocrine partner of palbociclib in practice, observedReport a problem
- Pilot Observational Study Examining the Effect of Endocrine Therapy on AgingCompletedUniversity of MichiganNCT05700006One aromatase inhibitor; ageing measures observedReport a problem
- A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNovartis PharmaceuticalsNCT06311383One endocrine partner of ribociclib in German practice, observedReport a problem
- A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingPfizerNCT06495164One aromatase inhibitor, alone or with a CDK4/6 inhibitor, in US recordsReport a problem
- Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.CompletedPfizerNCT06086340One aromatase inhibitor, alone or with palbociclib, in Medicare recordsReport a problem
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/LetrozoleCompletedBrigham and Women's HospitalNCT05635357The reference group against anastrozole, dementia risk in claimsWritten as Exemestane/LetrozoleReport a problem
- Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal DatabaseCompletedSidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01937052One hormone therapy in a longitudinal databaseReport a problem
- Effects of Exemestane on Bone StrengthCompletedUniversity Health Network, TorontoNCT01144468Its effect on bone strength in women taking it to prevent breast cancerReport a problem
- Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer PatientsCompletedUniversity of Michigan Rogel Cancer CenterNCT01814397One aromatase inhibitor; pain threshold observedWritten as exemestaneReport a problem
- Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerCompletedMayo ClinicNCT00719966One aromatase inhibitor; blood vessel function observedWritten as exemestaneReport a problem
- Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3CompletedNCIC Clinical Trials GroupNCT00688246Bone density in women taking it to prevent breast cancer, observedReport a problem
- Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast CancerCompletedEastern Cooperative Oncology GroupNCT00090974One of two aromatase inhibitors; quality of life observedReport a problem
- Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.CompletedBlokhin's Russian Cancer Research CenterNCT05789771One endocrine partner of abemaciclib in Russian practice, observedReport a problem
- Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyCompletedNovartis PharmaceuticalsNCT02753686One endocrine therapy in Canadian practice, observedReport a problem
- Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast CancerStatus unknownSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04891731One aromatase inhibitor with leuprorelin, observedReport a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownBlokhin's Russian Cancer Research CenterNCT04852081One endocrine therapy in treatment sequences, observedWritten as ExemestaneReport a problem
- Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the BreastStatus unknownFirst Hospital of China Medical UniversityNCT04666805One endocrine therapy in DCIS; its duration observedWritten as ExemestaneReport a problem
- Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast CancerStatus unknownInstituto Jalisciense de CancerologiaNCT04389424Nutrition and gene expression in women taking it, observedWritten as ExemestaneReport a problem
- 500mg Fulvestrant Versus Exemestane in MBCCompletedFudan UniversityNCT03575260Against fulvestrant, observedReport a problem
Showing 20 of 43. See all 43 →
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Codes
What other systems call exemestane · ClinicalTrials.gg INT003387
- MeSH (NLM) C056516exemestaneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) NY22HMQ4BXEXEMESTANEConfirmed FDA, NLM, Wikidata
- RxNorm 258494Confirmed FDA, Wikidata
- Wikidata Q418819exemestaneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1097ExemestaneOne source FDA
- DrugBank DB00990One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C056516 | exemestane | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | NY22HMQ4BX | EXEMESTANE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 258494 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418819 | exemestane | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1097 | Exemestane | One source FDA |
| DrugBank | DB00990 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.